Pulmonary Drugs Market Research Report - Global Forecast to 2025 - Cumulative Impact of COVID-19
Market Statistics:
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Pulmonary Drugs Market is expected to grow from USD 53,214.48 Million in 2020 to USD 59,313.83 Million by the end of 2025.
2. The Global Pulmonary Drugs Market is expected to grow from EUR 46,659.47 Million in 2020 to EUR 52,007.49 Million by the end of 2025.
3. The Global Pulmonary Drugs Market is expected to grow from GBP 41,480.37 Million in 2020 to GBP 46,234.77 Million by the end of 2025.
4. The Global Pulmonary Drugs Market is expected to grow from JPY 5,679,334.10 Million in 2020 to JPY 6,330,288.71 Million by the end of 2025.
5. The Global Pulmonary Drugs Market is expected to grow from AUD 77,274.51 Million in 2020 to AUD 86,131.57 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Pulmonary Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Geography, the Pulmonary Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Drugs Market including AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., F.Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Mallinckrodt Pharmaceuticals, Merck & Co., Novartis International AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Inc.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pulmonary Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Pulmonary Drugs Market?
The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.
1. The Global Pulmonary Drugs Market is expected to grow from USD 53,214.48 Million in 2020 to USD 59,313.83 Million by the end of 2025.
2. The Global Pulmonary Drugs Market is expected to grow from EUR 46,659.47 Million in 2020 to EUR 52,007.49 Million by the end of 2025.
3. The Global Pulmonary Drugs Market is expected to grow from GBP 41,480.37 Million in 2020 to GBP 46,234.77 Million by the end of 2025.
4. The Global Pulmonary Drugs Market is expected to grow from JPY 5,679,334.10 Million in 2020 to JPY 6,330,288.71 Million by the end of 2025.
5. The Global Pulmonary Drugs Market is expected to grow from AUD 77,274.51 Million in 2020 to AUD 86,131.57 Million by the end of 2025.
Market Segmentation & Coverage:
This research report categorizes the Pulmonary Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Geography, the Pulmonary Drugs Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.
Company Usability Profiles:
The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Pulmonary Drugs Market including AstraZeneca plc, Bayer AG, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co., F.Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Mallinckrodt Pharmaceuticals, Merck & Co., Novartis International AG, Pfizer Inc., Sanofi S.A, Teva Pharmaceutical Industries Ltd., and Vertex Pharmaceuticals Inc.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.
360iResearch FPNV Positioning Matrix:
The 360iResearch FPNV Positioning Matrix evaluates and categorizes the vendors in the Pulmonary Drugs Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
360iResearch Competitive Strategic Window:
The 360iResearch Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The 360iResearch Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Pulmonary Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Pulmonary Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Pulmonary Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Pulmonary Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Pulmonary Drugs Market?
6. What are the modes and strategic moves considered suitable for entering the Global Pulmonary Drugs Market?
1. PREFACE
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Geography Outlook
3.4. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of chronic respiratory diseases, tobacco smoking
5.1.1.2. Drug innovation and availability of Biosimilars
5.1.1.3. Government and non-government initiatives
5.1.2. Restraints
5.1.2.1. Patent expiry of drugs
5.1.3. Opportunities
5.1.3.1. Increasing disposable income and rising investments in R&D
5.1.3.2. Increasing healthcare spending
5.1.3.3. Drug development through contract manufacturing
5.1.4. Challenges
5.1.4.1. Expensive clinical trials and commercialization of new drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. AMERICAS PULMONARY DRUGS MARKET
6.1. Introduction
6.2. Argentina
6.3. Brazil
6.4. Canada
6.5. Mexico
6.6. United States
7. ASIA-PACIFIC PULMONARY DRUGS MARKET
7.1. Introduction
7.2. Australia
7.3. China
7.4. India
7.5. Indonesia
7.6. Japan
7.7. Malaysia
7.8. Philippines
7.9. South Korea
7.10. Thailand
8. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET
8.1. Introduction
8.2. France
8.3. Germany
8.4. Italy
8.5. Netherlands
8.6. Qatar
8.7. Russia
8.8. Saudi Arabia
8.9. South Africa
8.10. Spain
8.11. United Arab Emirates
8.12. United Kingdom
9. COMPETITIVE LANDSCAPE
9.1. FPNV Positioning Matrix
9.1.1. Quadrants
9.1.2. Business Strategy
9.1.3. Product Satisfaction
9.2. Market Ranking Analysis
9.3. Market Share Analysis
9.4. Competitor SWOT Analysis
9.5. Competitive Scenario
9.5.1. Merger & Acquisition
9.5.2. Agreement, Collaboration, & Partnership
9.5.3. New Product Launch & Enhancement
9.5.4. Investment & Funding
9.5.5. Award, Recognition, & Expansion
10. COMPANY USABILITY PROFILES
10.1. AstraZeneca plc
10.2. Bayer AG
10.3. Boehringer Ingelheim GmbH
10.4. Bristol-Myers Squibb Co.
10.5. F.Hoffmann-La Roche Ltd.
10.6. Gilead Sciences Inc.
10.7. GlaxoSmithKline plc
10.8. Mallinckrodt Pharmaceuticals
10.9. Merck & Co.
10.10. Novartis International AG
10.11. Pfizer Inc.
10.12. Sanofi S.A
10.13. Teva Pharmaceutical Industries Ltd.
10.14. Vertex Pharmaceuticals Inc
11. APPENDIX
11.1. Discussion Guide
11.2. License & Pricing
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Process
2.1.1. Define: Research Objective
2.1.2. Determine: Research Design
2.1.3. Prepare: Research Instrument
2.1.4. Collect: Data Source
2.1.5. Analyze: Data Interpretation
2.1.6. Formulate: Data Verification
2.1.7. Publish: Research Report
2.1.8. Repeat: Report Update
2.2. Research Execution
2.2.1. Initiation: Research Process
2.2.2. Planning: Develop Research Plan
2.2.3. Execution: Conduct Research
2.2.4. Verification: Finding & Analysis
2.2.5. Publication: Research Report
2.3. Research Outcome
3. EXECUTIVE SUMMARY
3.1. Introduction
3.2. Market Outlook
3.3. Geography Outlook
3.4. Competitor Outlook
4. MARKET OVERVIEW
4.1. Introduction
4.2. Cumulative Impact of COVID-19
5. MARKET INSIGHTS
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of chronic respiratory diseases, tobacco smoking
5.1.1.2. Drug innovation and availability of Biosimilars
5.1.1.3. Government and non-government initiatives
5.1.2. Restraints
5.1.2.1. Patent expiry of drugs
5.1.3. Opportunities
5.1.3.1. Increasing disposable income and rising investments in R&D
5.1.3.2. Increasing healthcare spending
5.1.3.3. Drug development through contract manufacturing
5.1.4. Challenges
5.1.4.1. Expensive clinical trials and commercialization of new drugs
5.2. Porters Five Forces Analysis
5.2.1. Threat of New Entrants
5.2.2. Threat of Substitutes
5.2.3. Bargaining Power of Customers
5.2.4. Bargaining Power of Suppliers
5.2.5. Industry Rivalry
6. AMERICAS PULMONARY DRUGS MARKET
6.1. Introduction
6.2. Argentina
6.3. Brazil
6.4. Canada
6.5. Mexico
6.6. United States
7. ASIA-PACIFIC PULMONARY DRUGS MARKET
7.1. Introduction
7.2. Australia
7.3. China
7.4. India
7.5. Indonesia
7.6. Japan
7.7. Malaysia
7.8. Philippines
7.9. South Korea
7.10. Thailand
8. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET
8.1. Introduction
8.2. France
8.3. Germany
8.4. Italy
8.5. Netherlands
8.6. Qatar
8.7. Russia
8.8. Saudi Arabia
8.9. South Africa
8.10. Spain
8.11. United Arab Emirates
8.12. United Kingdom
9. COMPETITIVE LANDSCAPE
9.1. FPNV Positioning Matrix
9.1.1. Quadrants
9.1.2. Business Strategy
9.1.3. Product Satisfaction
9.2. Market Ranking Analysis
9.3. Market Share Analysis
9.4. Competitor SWOT Analysis
9.5. Competitive Scenario
9.5.1. Merger & Acquisition
9.5.2. Agreement, Collaboration, & Partnership
9.5.3. New Product Launch & Enhancement
9.5.4. Investment & Funding
9.5.5. Award, Recognition, & Expansion
10. COMPANY USABILITY PROFILES
10.1. AstraZeneca plc
10.2. Bayer AG
10.3. Boehringer Ingelheim GmbH
10.4. Bristol-Myers Squibb Co.
10.5. F.Hoffmann-La Roche Ltd.
10.6. Gilead Sciences Inc.
10.7. GlaxoSmithKline plc
10.8. Mallinckrodt Pharmaceuticals
10.9. Merck & Co.
10.10. Novartis International AG
10.11. Pfizer Inc.
10.12. Sanofi S.A
10.13. Teva Pharmaceutical Industries Ltd.
10.14. Vertex Pharmaceuticals Inc
11. APPENDIX
11.1. Discussion Guide
11.2. License & Pricing
LIST OF TABLES
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL PULMONARY DRUGS MARKET: SCORES
TABLE 8. GLOBAL PULMONARY DRUGS MARKET: BUSINESS STRATEGY
TABLE 9. GLOBAL PULMONARY DRUGS MARKET: PRODUCT SATISFACTION
TABLE 10. GLOBAL PULMONARY DRUGS MARKET: RANKING
TABLE 11. GLOBAL PULMONARY DRUGS MARKET: MERGER & ACQUISITION
TABLE 12. GLOBAL PULMONARY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 13. GLOBAL PULMONARY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 14. GLOBAL PULMONARY DRUGS MARKET: INVESTMENT & FUNDING
TABLE 15. GLOBAL PULMONARY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 16. GLOBAL PULMONARY DRUGS MARKET: LICENSE & PRICING
TABLE 1. CURRENCY CONVERSION RATES
TABLE 2. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 4. AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 5. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 6. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD/EUR/GBP/JPY/AUD MILLION)
TABLE 7. GLOBAL PULMONARY DRUGS MARKET: SCORES
TABLE 8. GLOBAL PULMONARY DRUGS MARKET: BUSINESS STRATEGY
TABLE 9. GLOBAL PULMONARY DRUGS MARKET: PRODUCT SATISFACTION
TABLE 10. GLOBAL PULMONARY DRUGS MARKET: RANKING
TABLE 11. GLOBAL PULMONARY DRUGS MARKET: MERGER & ACQUISITION
TABLE 12. GLOBAL PULMONARY DRUGS MARKET: AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 13. GLOBAL PULMONARY DRUGS MARKET: NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 14. GLOBAL PULMONARY DRUGS MARKET: INVESTMENT & FUNDING
TABLE 15. GLOBAL PULMONARY DRUGS MARKET: AWARD, RECOGNITION, & EXPANSION
TABLE 16. GLOBAL PULMONARY DRUGS MARKET: LICENSE & PRICING
LIST OF FIGURES
FIGURE 1. GLOBAL PULMONARY DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PULMONARY DRUGS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 9. GLOBAL PULMONARY DRUGS MARKET: MARKET DYNAMICS
FIGURE 10. GLOBAL PULMONARY DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 11. AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 12. AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 14. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 15. BRAZIL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 16. CANADA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 17. MEXICO PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 18. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 20. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 22. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 23. CHINA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 24. INDIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 25. INDONESIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 26. JAPAN PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 27. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 28. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 29. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 30. THAILAND PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 34. FRANCE PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 35. GERMANY PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 36. ITALY PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. QATAR PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. RUSSIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. SPAIN PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 44. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. GLOBAL PULMONARY DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 46. GLOBAL PULMONARY DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 47. GLOBAL PULMONARY DRUGS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PULMONARY DRUGS MARKET, BY TYPE
FIGURE 1. GLOBAL PULMONARY DRUGS MARKET: RESEARCH PROCESS
FIGURE 2. GLOBAL PULMONARY DRUGS MARKET: RESEARCH EXECUTION
FIGURE 3. GLOBAL PULMONARY DRUGS MARKET SIZE, 2020 VS 2025 (USD MILLION)
FIGURE 4. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 (USD MILLION)
FIGURE 5. GLOBAL PULMONARY DRUGS MARKET SIZE, 2018-2025 (USD MILLION)
FIGURE 6. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 7. GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 8. COMPETITIVE STRATEGIC WINDOW FOR GLOBAL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 9. GLOBAL PULMONARY DRUGS MARKET: MARKET DYNAMICS
FIGURE 10. GLOBAL PULMONARY DRUGS MARKET: PORTERS FIVE FORCES ANALYSIS
FIGURE 11. AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 12. AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 13. COMPETITIVE STRATEGIC WINDOW FOR AMERICAS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 14. ARGENTINA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 15. BRAZIL PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 16. CANADA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 17. MEXICO PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 18. UNITED STATES PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 19. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 20. ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 21. COMPETITIVE STRATEGIC WINDOW FOR ASIA-PACIFIC PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 22. AUSTRALIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 23. CHINA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 24. INDIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 25. INDONESIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 26. JAPAN PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 27. MALAYSIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 28. PHILIPPINES PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 29. SOUTH KOREA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 30. THAILAND PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 31. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (%)
FIGURE 32. EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2020 VS 2025 (USD MILLION)
FIGURE 33. COMPETITIVE STRATEGIC WINDOW FOR EUROPE, MIDDLE EAST & AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2025
FIGURE 34. FRANCE PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 35. GERMANY PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 36. ITALY PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 37. NETHERLANDS PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 38. QATAR PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 39. RUSSIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 40. SAUDI ARABIA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 41. SOUTH AFRICA PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 42. SPAIN PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 43. UNITED ARAB EMIRATES PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 44. UNITED KINGDOM PULMONARY DRUGS MARKET SIZE, BY GEOGRAPHY, 2018-2025 (USD MILLION)
FIGURE 45. GLOBAL PULMONARY DRUGS MARKET: 360IRESEARCH FPNV POSITIONING MATRIX
FIGURE 46. GLOBAL PULMONARY DRUGS MARKET: 360IRESEARCH MARKET SHARE ANALYSIS
FIGURE 47. GLOBAL PULMONARY DRUGS MARKET: COMPETITOR SWOT ANALYSIS
FIGURE 48. COMPETITIVE SCENARIO ANALYSIS IN GLOBAL PULMONARY DRUGS MARKET, BY TYPE
